DOP2009000222A - Formulaciones estables de anticuerpo - Google Patents
Formulaciones estables de anticuerpoInfo
- Publication number
- DOP2009000222A DOP2009000222A DO2009000222A DO2009000222A DOP2009000222A DO P2009000222 A DOP2009000222 A DO P2009000222A DO 2009000222 A DO2009000222 A DO 2009000222A DO 2009000222 A DO2009000222 A DO 2009000222A DO P2009000222 A DOP2009000222 A DO P2009000222A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- antibody
- formulations
- insulin
- receptor
- stabilization
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 238000009472 formulation Methods 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 2
- 230000006641 stabilisation Effects 0.000 abstract 2
- 238000011105 stabilization Methods 0.000 abstract 2
- 102000038455 IGF Type 1 Receptor Human genes 0.000 abstract 1
- 108010031794 IGF Type 1 Receptor Proteins 0.000 abstract 1
- 239000013011 aqueous formulation Substances 0.000 abstract 1
- 230000002608 insulinlike Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91974407P | 2007-03-22 | 2007-03-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2009000222A true DOP2009000222A (es) | 2009-12-15 |
Family
ID=39766776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2009000222A DOP2009000222A (es) | 2007-03-22 | 2009-09-18 | Formulaciones estables de anticuerpo |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20100260766A1 (OSRAM) |
| EP (1) | EP2136839A4 (OSRAM) |
| JP (1) | JP2010522208A (OSRAM) |
| KR (1) | KR20090113340A (OSRAM) |
| CN (1) | CN101668540A (OSRAM) |
| AU (1) | AU2008228823A1 (OSRAM) |
| BR (1) | BRPI0809112A2 (OSRAM) |
| CA (1) | CA2681743A1 (OSRAM) |
| CR (1) | CR11005A (OSRAM) |
| DO (1) | DOP2009000222A (OSRAM) |
| EA (1) | EA200970880A1 (OSRAM) |
| EC (1) | ECSP099642A (OSRAM) |
| IL (1) | IL200321A0 (OSRAM) |
| MX (1) | MX2009010179A (OSRAM) |
| TN (1) | TN2009000382A1 (OSRAM) |
| UA (1) | UA96473C2 (OSRAM) |
| WO (1) | WO2008116103A2 (OSRAM) |
| ZA (1) | ZA200905636B (OSRAM) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160279239A1 (en) | 2011-05-02 | 2016-09-29 | Immunomedics, Inc. | Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| TW200838559A (en) * | 2006-11-29 | 2008-10-01 | Imclone Systems Inc | Insulin-like growth factor-1 receptor antagonists for modulation of weight and liposity |
| PE20090368A1 (es) | 2007-06-19 | 2009-04-28 | Boehringer Ingelheim Int | Anticuerpos anti-igf |
| EP4104821A1 (en) * | 2008-10-29 | 2022-12-21 | Ablynx N.V. | Formulations of single domain antigen binding molecules |
| CA2739352C (en) | 2008-10-29 | 2021-07-13 | Wyeth Llc | Methods for purification of single domain antigen binding molecules |
| CN102438652B (zh) * | 2008-11-12 | 2014-08-13 | 米迪缪尼有限公司 | 抗体制剂 |
| EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| RS54423B1 (sr) | 2008-12-12 | 2016-04-28 | Boehringer Ingelheim International Gmbh | Anti-igf antitela |
| AR080428A1 (es) | 2010-01-20 | 2012-04-11 | Chugai Pharmaceutical Co Ltd | Formulaciones liquidas estabilizadas contentivas de anticuerpos |
| WO2012028683A1 (en) | 2010-09-02 | 2012-03-08 | Novartis Ag | Antibody gel system for sustained drug delivery |
| EA027353B1 (ru) | 2010-09-17 | 2017-07-31 | Баксалта Инкорпорейтид | СТАБИЛИЗАЦИЯ ИММУНОГЛОБУЛИНОВ С ПОМОЩЬЮ ВОДНОГО СОСТАВА С ГИСТИДИНОМ ПРИ pH ОТ СЛАБОКИСЛОГО ДО НЕЙТРАЛЬНОГО |
| KR20180129991A (ko) | 2010-11-05 | 2018-12-05 | 노파르티스 아게 | Ｉｌ-１７ 길항제를 사용한 류마티스성 관절염의 치료 방법 |
| WO2012151199A1 (en) | 2011-05-02 | 2012-11-08 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
| CN104136047B (zh) * | 2011-10-26 | 2018-02-06 | 安姆根有限公司 | 减少或消除由暴露于uv光而引起的蛋白质修饰和降解的方法 |
| EP3378535B1 (en) | 2011-10-28 | 2023-01-04 | Prothena Biosciences Limited | Humanized antibodies that recognize alpha-synuclein |
| KR102086061B1 (ko) | 2012-01-27 | 2020-03-11 | 프로테나 바이오사이언시즈 리미티드 | 알파-시누클레인을 인식하는 인간화된 항체 |
| AR091902A1 (es) * | 2012-07-25 | 2015-03-11 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de un conjugado de insulina de accion prolongada |
| AR092862A1 (es) * | 2012-07-25 | 2015-05-06 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion |
| AR094821A1 (es) * | 2012-07-25 | 2015-09-02 | Hanmi Pharm Ind Co Ltd | Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada |
| UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| CN104870469A (zh) | 2012-12-26 | 2015-08-26 | 沃克哈特有限公司 | 药物组合物 |
| US20140255413A1 (en) | 2013-03-07 | 2014-09-11 | Boehringer Ingelheim International Gmbh | Combination therapy for neoplasia treatment |
| US9700485B2 (en) | 2013-04-24 | 2017-07-11 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| NL1040254C2 (en) * | 2013-05-17 | 2014-11-24 | Ablynx Nv | Stable formulations of immunoglobulin single variable domains and uses thereof. |
| US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| WO2015155694A1 (en) | 2014-04-08 | 2015-10-15 | Prothena Biosciences Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
| EA202092609A1 (ru) | 2014-12-04 | 2021-10-29 | Янссен Байотек, Инк. | Антитела к cd38 для лечения острого миелолейкоза |
| CA2973423C (en) * | 2015-02-09 | 2023-09-05 | Ucb Biopharma Sprl | Pharmaceutical formulation |
| CN108136218B (zh) | 2015-05-20 | 2022-12-13 | 詹森生物科技公司 | 用于治疗轻链淀粉样变性及其它cd38阳性血液恶性肿瘤的抗cd38抗体 |
| AR104847A1 (es) * | 2015-06-17 | 2017-08-16 | Lilly Co Eli | Formulación de anticuerpo anti-cgrp |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| RS61651B1 (sr) | 2015-11-03 | 2021-04-29 | Janssen Biotech Inc | Potkožne formulacije anti-cd38 antitela i njihova upotreba |
| JP6992262B2 (ja) * | 2016-03-31 | 2022-02-15 | 東ソー株式会社 | 変性抗体測定試薬の製造方法 |
| EP3606964A4 (en) | 2017-04-03 | 2020-12-09 | Immunomedics, Inc. | SUBCUTANE ADMINISTRATION OF ANTIBODY DRUG CONJUGATES FOR CANCER THERAPY |
| JP2021502961A (ja) | 2017-10-31 | 2021-02-04 | ヤンセン バイオテツク，インコーポレーテツド | 高リスク多発性骨髄腫の治療方法 |
| JP7266108B2 (ja) | 2019-02-18 | 2023-04-27 | イーライ リリー アンド カンパニー | 治療用抗体製剤 |
| CN112206320B (zh) * | 2019-07-12 | 2025-02-25 | 鲁南制药集团股份有限公司 | 一种cd47单克隆抗体冻干粉制剂及其制备工艺 |
| CN113967195A (zh) * | 2020-07-22 | 2022-01-25 | 三生国健药业（上海）股份有限公司 | 抗her2/pd1双特异性抗体冻干制剂及其制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0565233A (ja) * | 1991-03-08 | 1993-03-19 | Mitsui Toatsu Chem Inc | モノクローナル抗体含有凍結乾燥製剤 |
| DE122004000008I1 (de) * | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| JP4340062B2 (ja) * | 2000-10-12 | 2009-10-07 | ジェネンテック・インコーポレーテッド | 粘度の減少した濃縮タンパク質製剤 |
| NZ530765A (en) * | 2001-06-26 | 2006-11-30 | Amgen Fremont Inc | Antibodies that bind OPGL and compositions and methods for the treatment of bone diseases |
| US20030113316A1 (en) * | 2001-07-25 | 2003-06-19 | Kaisheva Elizabet A. | Stable lyophilized pharmaceutical formulation of IgG antibodies |
| MXPA04007924A (es) * | 2002-02-14 | 2005-05-17 | Chugai Pharmaceutical Co Ltd | Formulaciones en solucion que contienen anticuerpo. |
| KR20070086866A (ko) * | 2003-02-13 | 2007-08-27 | 화이자 프로덕츠 인크. | 항-인슐린양 성장인자 ｉ 수용체 항체의 용도 |
| CA2524305C (en) * | 2003-05-01 | 2015-12-08 | Imclone Systems Incorporated | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
| AR046071A1 (es) * | 2003-07-10 | 2005-11-23 | Hoffmann La Roche | Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos |
| ES2351395T3 (es) * | 2003-08-13 | 2011-02-04 | Pfizer Products Inc. | Anticuerpos humanos modificados anti-igf-1r. |
| CA2607663C (en) * | 2005-05-19 | 2014-08-12 | Amgen Inc. | Compositions and methods for increasing the stability of antibodies |
| CN101287761A (zh) * | 2005-06-15 | 2008-10-15 | 先灵公司 | 抗-igf1r抗体制剂 |
| RU2008142359A (ru) * | 2006-03-28 | 2010-05-10 | Ф.Хоффманн-Ля Рош Аг (Ch) | Композиция человеческого моноклонального антитела к igf-1r |
-
2008
- 2008-03-20 UA UAA200909552A patent/UA96473C2/ru unknown
- 2008-03-20 BR BRPI0809112-9A patent/BRPI0809112A2/pt not_active IP Right Cessation
- 2008-03-20 WO PCT/US2008/057718 patent/WO2008116103A2/en not_active Ceased
- 2008-03-20 KR KR1020097019642A patent/KR20090113340A/ko not_active Abandoned
- 2008-03-20 MX MX2009010179A patent/MX2009010179A/es not_active Application Discontinuation
- 2008-03-20 AU AU2008228823A patent/AU2008228823A1/en not_active Abandoned
- 2008-03-20 JP JP2009554753A patent/JP2010522208A/ja active Pending
- 2008-03-20 EP EP08744136A patent/EP2136839A4/en not_active Withdrawn
- 2008-03-20 EA EA200970880A patent/EA200970880A1/ru unknown
- 2008-03-20 CN CN200880009446A patent/CN101668540A/zh active Pending
- 2008-03-20 CA CA002681743A patent/CA2681743A1/en not_active Abandoned
- 2008-03-20 US US12/528,882 patent/US20100260766A1/en not_active Abandoned
-
2009
- 2009-08-10 IL IL200321A patent/IL200321A0/en unknown
- 2009-08-13 ZA ZA200905636A patent/ZA200905636B/xx unknown
- 2009-08-28 CR CR11005A patent/CR11005A/es not_active Application Discontinuation
- 2009-09-18 TN TNP2009000382A patent/TN2009000382A1/fr unknown
- 2009-09-18 DO DO2009000222A patent/DOP2009000222A/es unknown
- 2009-09-21 EC EC2009009642A patent/ECSP099642A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101668540A (zh) | 2010-03-10 |
| BRPI0809112A2 (pt) | 2014-08-26 |
| ZA200905636B (en) | 2010-10-27 |
| EP2136839A2 (en) | 2009-12-30 |
| EP2136839A4 (en) | 2010-04-07 |
| ECSP099642A (es) | 2009-11-30 |
| US20100260766A1 (en) | 2010-10-14 |
| AU2008228823A1 (en) | 2008-09-25 |
| JP2010522208A (ja) | 2010-07-01 |
| UA96473C2 (ru) | 2011-11-10 |
| KR20090113340A (ko) | 2009-10-29 |
| EA200970880A1 (ru) | 2010-02-26 |
| CR11005A (es) | 2010-08-05 |
| CA2681743A1 (en) | 2008-09-25 |
| WO2008116103A2 (en) | 2008-09-25 |
| IL200321A0 (en) | 2010-04-29 |
| MX2009010179A (es) | 2010-03-15 |
| WO2008116103A3 (en) | 2009-01-08 |
| TN2009000382A1 (en) | 2010-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2009000222A (es) | Formulaciones estables de anticuerpo | |
| CY1123909T1 (el) | Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα κατα του υποδοχεα της ιντερλευκινης-6 (il-6r) | |
| AR130402A2 (es) | Formulaciones de anticuerpos anti-pdl1 | |
| AR095451A1 (es) | Formulación de anticuerpos | |
| CY1122181T1 (el) | Φαρμακοτεχνικη μορφη αντισωματος | |
| AR124140A2 (es) | Formulaciones de anticuerpos | |
| CY1124844T1 (el) | Φαρμακευτικο σκευασμα αντισωματος | |
| CY1121233T1 (el) | Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα καtα του υποδοχεα iντερλευκinης-4(ιl-4r) | |
| WO2012076670A3 (en) | Antibody formulation | |
| JO3449B1 (ar) | صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب | |
| AR089787A1 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-ang2 | |
| WO2010100200A3 (en) | Lyophilised antibody formulation | |
| AR086823A1 (es) | Formulaciones de anticuerpo anti-c-met, metodos | |
| WO2011109365A3 (en) | Concentrated protein formulations and uses thereof | |
| PE20120359A1 (es) | Formulacion con anticuerpo | |
| UY32609A (es) | Formulaciones estables de anticuerpos anti-tnf-alfa humanos con grandes concentraciones de proteína | |
| AR095396A1 (es) | Formulaciones de anticuerpo | |
| AR091530A1 (es) | Formulacion farmaceutica liquida de un anticuerpo y acetato | |
| EA201492186A1 (ru) | СОДЕРЖАЩИЕ АНТИТЕЛА К Dll4 СТАБИЛИЗИРОВАННЫЕ КОМПОЗИЦИИ | |
| ECSP21043639A (es) | Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf | |
| AR130115A2 (es) | Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf | |
| AR122036A2 (es) | Composiciones farmacéuticas estables para la administración intratecal de arisulfatasa a |